Sangamo–Leucadia: investor conference, 201911 supply service Sangamo at Jefferies London Healthcare Conference 2019

	Period	2019-11-21
	Region	London, Greater London
	Country	United Kingdom (GB)
	Partner, 1st	Jefferies LLC
	Group	Leucadia (Group)
	Product	Jefferies 2019 London Healthcare Conference
	Product 2	cell therapy

Sangamo Therapeutics, Inc.. (11/18/19). "Press Release: Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference". Brisbane, CA.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London, UK.

The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com.

Investor Relations – Global
McDavid Stilwell
510-970-6000, x219
mstilwell@sangamo.com

Media Inquiries – Global
Aron Feingold
510-970-6000, x421
afeingold@sangamo.com

Record changed: 2019-11-27

More documents for Sangamo (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)